Trial Profile
Remicade Safety Line
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Merck & Co; Schering-Plough
- 31 Jan 2012 Actual patient number (576) added as reported by ClinicalTrials.gov.
- 31 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jul 2010 New trial record